İlhan Sabancılar | Molecular Oncology | Best Researcher Award

Published on by Global Academic Awards

Assist. Prof. Dr. İlhan Sabancılar | Molecular Oncology | Best Researcher Award

Bitlis Eren University | Turkey

Assist. Prof. Dr. İlhan Sabancılar is a biochemist and medical researcher at Bitlis Eren University, Turkey, whose work bridges biochemistry, molecular medicine, and pharmaceutical sciences. His research primarily focuses on the anticancer, antioxidant, antimicrobial, and anti-inflammatory properties of bioactive compounds, natural extracts, and nanomaterials. Assist. Prof. Dr. İlhan Sabancılar has contributed to the synthesis and biological evaluation of novel heterocyclic and aza-acyclic nucleoside derivatives, investigating their potential as therapeutic agents through molecular docking and cytotoxicity studies. His publications in journals such as Pharmaceuticals, Current Issues in Molecular Biology, and Reviews on Environmental Health reflect his expertise in oxidative stress, trace element biochemistry, and drug development. With 9 publications and 247 citations, he has established a growing scientific presence supported by multiple research projects on oxidative stress, viral inhibition, and cancer therapeutics. A member of the Turkish Biochemical Society and the Molecular Cancer Research Association, Assist. Prof. Dr. İlhan Sabancılar’s multidisciplinary approach and consistent research output position him as a promising scholar contributing significantly to the advancement of biomedical and biochemical sciences.

Profile: Scopus | Orcid | Google Scholar

Featured Publications

1. Unsal, V., Cicek, M., & Sabancilar, İ. (2021). Toxicity of carbon tetrachloride, free radicals and role of antioxidants. Reviews on Environmental Health, 36(2), 279–295.

2. Bilden, A., Sabancılar, İ., Yalçın Azarkan, S., Karadağlı, K., Kaya, S., Kahraman, M., & Çiçek, M. (2025). Investigating the therapeutic potential of crude leech saliva based on its anticancer, antioxidant, and anti-inflammatory effects. Current Issues in Molecular Biology, 47(5), 328.

3. Sabancilar, İ., Unsal, V., Demir, F., Toprak, G., & Pekkolay, Z. (2023). Does oxidative status affect serum sclerostin levels in patients with type 2 diabetes mellitus? Folia Medica, 65(1), 46–52.

4. Alhilal, M., Alhilal, S., Gomha, S. M., Farag, B., Sabancilar, İ., & Ouf, S. A. (2025). Biological evaluation and molecular docking studies of novel aza-acyclic nucleosides as putative antimicrobial, anticancer, and antioxidant agents. BMC Chemistry, 19(1), 255.

5. Muhammed Ayral, H. T., Toprak, S. F., Dedeoğlu, S., & Sabancılar, İ. (2021). Kronik Otitis Media’da Tiyol-Disülfid Homeostazının Değişikliği. Dicle Tıp Dergisi, 48(1), 197–204.

6. Toprak, G., Sabancılar, İ., Özcan, N., & Alkan, H. (2020). Total oxidant status (TOS), total antioxidant status (TAS), ferritin and vitamin D levels in patients with chronic hepatitis C. Microbiology and Infectious Diseases, 4(2), 1–4.

 

Richard Moore | Gynecologic Oncology | Leadership in Research Excellence Award

Published on by Global Academic Awards

Dr. Richard Moore | Gynecologic Oncology | Leadership in Research Excellence Award

University of Rochester | United States

Dr. Richard Moore is a distinguished leader in gynecologic oncology, renowned for his pioneering research, academic excellence, and leadership in translational medicine. He earned degrees in mechanical and industrial engineering before pursuing biology and obtaining his MD from the University of Alberta. His postgraduate training at Eastern Virginia Graduate School of Medicine and fellowship at Brown University established his foundation in women’s oncology. Over his illustrious career, Dr. Richard Moore has held prestigious roles, including Director of the Molecular Therapeutics Laboratory and Center for Biomarkers and Emerging Technology at Brown University, and currently serves as Chief of Gynecologic Oncology and Director of the Targeted Therapeutics Laboratory for Gynecologic Cancers at the University of Rochester Medical Center. A tenured professor, he has contributed significantly to advancing targeted therapeutics, biomarker discovery, and patient-centered oncology care. His work has earned numerous awards, international recognition, and over 8,037 citations from 135 publications and an impressive h-index of 39.

Profile: Scopus

Featured Publications

  • OVARIO Investigators, & Moore, R. G. (2025). A phase 2 trial of niraparib plus bevacizumab maintenance therapy following first-line platinum-based chemotherapy with bevacizumab in advanced ovarian cancer: Final analysis and overall survival results from OVARIO. Gynecologic Oncology.

  • NRG Oncology, & Moore, R. G. (2025). Pembrolizumab plus chemotherapy in advanced or recurrent endometrial cancer: Overall survival and exploratory analyses of the NRG GY018 phase 3 randomized trial. Nature Medicine.

  • Moore, R. G., et al. (2025). First-line lenvatinib plus pembrolizumab versus chemotherapy for advanced endometrial cancer: A randomized, open-label, phase III trial. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology.

  • Moore, R. G., et al. (2025). Endometrioid adenocarcinoma of the colon arising from rare malignant transformation of extra-gonadal endometrioma. Gynecologic Oncology Reports.

  • Moore, R. G., et al. (2025). Estrogen therapy in patients with gynecologic cancer: A survey of gynecologists and oncologists in the United States. Menopause.

Tianzhu Qiu | Oncology | Women Researcher Award

Published on by Global Academic Awards

Prof. Dr. Tianzhu Qiu | Oncology | Women Researcher Award

Prof. Dr. Tianzhu Qiu, the First Affiliated Hospital with Nanjing Medical University, China

Prof. Dr. Tianzhu Qiu is an esteemed oncology expert with a Ph.D. in Medicine from Nanjing Medical University. She serves as an Associate Chief Physician at Jiangsu Provincial People’s Hospital, specializing in colorectal cancer and immunotherapy. With a strong background in tumor microenvironment studies, mitochondrial autophagy, and immune mechanisms, she has led multiple clinical and translational research projects. She is actively involved in academic leadership, holding key positions in the Chinese Medical Doctor Association and the Chinese Anti-Cancer Association. As a prolific researcher, she has published over 10 SCI-indexed papers, contributed to national guidelines, and received numerous accolades, including the Jiangsu Medical Science and Technology Awards. Dr. Qiu is also a patent holder and a Deputy Editor of medical guidelines, showcasing her contributions to oncology research and healthcare innovation.

Publication Profile

Scopus

Education 🎓

Prof. Dr. Tianzhu Qiu earned her Ph.D. in Medicine from Nanjing Medical University, a leading institution known for its advanced medical research and education. Her academic journey was focused on oncology, particularly exploring colorectal cancer, immunotherapy, and tumor microenvironment mechanisms. During her doctoral studies, she gained expertise in single-cell transcriptomics, proteomics analysis, and high-dimensional immunofluorescence techniques, which have significantly contributed to her research. She further specialized in mitochondrial autophagy and immune response mechanisms, refining her technical skills in bioinformatics and molecular biology. Her Ph.D. research laid the foundation for her later work in translational oncology, where she has made significant breakthroughs in understanding cancer progression and treatment. Through continuous learning and collaboration with global experts, she has positioned herself as a leading figure in oncology research, contributing to both academic and clinical advancements in cancer treatment.

Experience 🏥

Dr. Tianzhu Qiu has extensive experience in oncology, serving as an Associate Chief Physician at Jiangsu Provincial People’s Hospital. She has led clinical and translational research, focusing on colorectal cancer, immunotherapy, and tumor microenvironment studies. Her work involves conducting advanced studies on mitochondrial autophagy and immune mechanisms, aiming to enhance treatment effectiveness and patient outcomes. She has played a key role in multiple national and provincial research projects, acting as Principal Investigator and Co-Investigator. Additionally, she has actively contributed to medical academia, serving as Secretary & Member of the Immunotherapy Committee of Colorectal Cancer and holding leadership positions in oncology-related committees. Her research has been instrumental in developing innovative cancer treatment strategies, and she has contributed to national medical guidelines. Through her experience, Dr. Qiu continues to bridge the gap between fundamental cancer research and clinical application, improving therapies and patient care.

Awards & Honors 🏆

Dr. Tianzhu Qiu has been recognized for her outstanding contributions to oncology with prestigious awards. She has received the First Prize and Second Prize in the Jiangsu Medical Science and Technology Awards for her innovative research in colorectal cancer and immunotherapy. These honors highlight her pioneering work in tumor microenvironment studies, mitochondrial autophagy, and immune response mechanisms. Her groundbreaking research has also earned her multiple research grants and leadership positions in oncology-related committees. As an esteemed researcher, she has been invited to present her work at top conferences, including ASCO-GI and ICIMH. Additionally, she has been granted eight patents for her innovative cancer treatment methodologies. Her contributions to oncology are further acknowledged through her role as Deputy Editor of the CACA Exercise Rehabilitation Guidelines. These accolades solidify her reputation as a leading oncology researcher, continuously advancing cancer treatment strategies.

Research Focus 🔬

Dr. Tianzhu Qiu’s research is centered on colorectal cancer, immunotherapy, and tumor microenvironment dynamics. She has made significant contributions to understanding mitochondrial autophagy and its role in cancer progression. Her work also involves single-cell transcriptomics and proteomics analysis, helping to uncover novel biomarkers and therapeutic targets. Utilizing advanced techniques such as multiplex immunofluorescence and high-dimensional bioinformatics, she has developed new approaches for cancer diagnosis and treatment. Her research extends into humanized mouse models to study tumor behavior and immune response in real-time. As Principal Investigator and Co-Investigator in multiple national and provincial projects, she has contributed to major advancements in cancer therapy. Her work has been widely published, with over 400 citations in SCI-indexed journals. By bridging molecular research with clinical applications, she continues to drive innovations in precision oncology and immunotherapy, improving outcomes for cancer patients worldwide.

 

Publication Top Notes

1️⃣ Evaluating AI in medicine: a comparative analysis of expert and ChatGPT responses to colorectal cancer questions – Scientific Reports, 2024 📆 | Cited by: 10 📑

2️⃣ Neoadjuvant sintilimab and chemotherapy in patients with potentially resectable esophageal squamous cell carcinoma (KEEP-G 03): An open-label, single-arm, phase 2 trial – Journal for ImmunoTherapy of Cancer, 2023 📆 | Cited by: 42 📑

Conclusion

Prof. Dr. Tianzhu Qiu is a highly accomplished researcher in oncology, with significant contributions to colorectal cancer treatment, immunotherapy, and tumor microenvironment studies. Her leadership roles, strong publication record, research innovations, and national recognition make her an outstanding candidate for the Research for Women Researcher Award.

Ashiq Ali | Oncology | Best Researcher Award

Published on by Global Academic Awards

Dr. Ashiq Ali | Oncology | Best Researcher Award

Dr. Ashiq Ali, Shantou University Medical College, China

Dr. Ashiq Ali is a dedicated postdoctoral fellow at Shantou University Medical College, China, with a strong academic background in Pathology and Immunology. He earned his Ph.D. in Pathology and Immunology from the University of Agriculture Faisalabad. With expertise in cancer epigenetics, immunoproteomics, and molecular diagnostics, he has significantly contributed to vaccine development and probiotic research. His commitment to advancing scientific knowledge is evident through numerous publications and successful research projects. As a passionate educator, Dr. Ali has experience mentoring students and conducting lectures on pathology and clinical diagnostics. His dedication to innovative research and academic excellence makes him a valuable contributor to the global scientific community. 📚🔬🧬

Publication Profile

Google Scholar

Education 🎓

Dr. Ashiq Ali pursued his Ph.D. in Pathology and Immunology (2017–2022) from the University of Agriculture Faisalabad, focusing on cancer epigenetics and immunoproteomics. Prior to that, he completed his M.Phil. in Pathology (2014–2016) at the same university, excelling in clinical diagnostics and molecular biology. His academic journey began with a Doctor of Veterinary Medicine (DVM) (2009–2014), where he developed a strong foundation in veterinary pathology, microbiology, and immunology. Throughout his education, Dr. Ali demonstrated exceptional dedication, earning prestigious scholarships and excelling in his research pursuits. His continuous pursuit of knowledge in pathological research and immunological studies highlights his commitment to contributing to the medical and scientific fields. 📘🧑‍🔬🔎

Experience 💼

Dr. Ashiq Ali is currently a postdoctoral fellow at Shantou University Medical College, China, conducting advanced research in pathology and immunology. From 2018 to 2019, he served as a Teaching Assistant at the University of Agriculture Faisalabad, where he conducted practical and theoretical classes on subjects like General Pathology, Clinical Pathology, and Oncology. Between 2016 and 2020, he contributed as a volunteer research assistant, gaining extensive hands-on experience in molecular diagnostics, PCR, immunohistochemistry, and virus cultivation. His role involved supervising laboratory operations, mentoring students, and conducting detailed investigations into infectious diseases, cancer research, and vaccine development. Dr. Ali’s dynamic experience across teaching, research, and lab management highlights his versatility and dedication to scientific advancements. 🧪🔎📊

Awards and Honors 🏆

Dr. Ashiq Ali’s academic excellence has been recognized through prestigious awards, including a Merit Scholarship during his M.Phil. in Pathology at the University of Agriculture Faisalabad (2014–2016). His exceptional research capabilities earned him the Indigenous Ph.D. Fellowship from the Higher Education Commission (HEC) of Pakistan (2018–2022), supporting his groundbreaking work in cancer epigenetics and immunology. These accolades underscore his academic dedication, research competence, and commitment to scientific growth. His contributions have not only elevated his academic standing but also significantly advanced the field of pathology and immunology. 🏅📚🧑‍🔬

Research Focus 🧬

Dr. Ashiq Ali’s research centers on cancer epigenetics, immunoproteomics, and molecular diagnostics, with a keen interest in tumor identification, immunohistochemistry, and gene expression analysis. His expertise includes the development of vaccines using plant-based adjuvants, investigating the therapeutic potential of interferon-alpha against viruses, and applying probiotics for mycotoxin biodegradation. Additionally, Dr. Ali explores the role of pathological markers in disease diagnosis and studies the effects of environmental toxins. His research contributions, particularly in advancing molecular and cellular pathology, continue to pave the way for innovative treatments in infectious diseases, oncology, and veterinary medicine. 🧫🧪🧑‍🔬

Publication Top Notes

  • 📖 Microbial and enzymatic battle with food contaminant zearalenone (ZEN) – Cited by: 23 – Year: 2022

  • 📖 In-vitro assessment of a novel plant rhizobacterium, Citrobacter freundii, for degrading and biocontrol of food mycotoxin deoxynivalenol – Cited by: 21 – Year: 2023

  • 📖 Prevalence, molecular characterization and antibiogram study of Listeria monocytogenes isolated from raw milk and milk products – Cited by: 18 – Year: 2020

  • 📖 Probiotics: Helpful for the prevention of COVID-19? – Cited by: 17 – Year: 2020

  • 📖 Green nanotechnology mediated silver and iron oxide nanoparticles: Potential antimicrobials – Cited by: 15 – Year: 2022

  • 📖 Type I IFNs: a blessing in disguise or partner in crime in MERS-CoV-, SARS-CoV-, and SARS-CoV-2-induced pathology and potential use of type I IFNs in synergism with IFN-γ – Cited by: 14 – Year: 2021

  • 📖 Potassium use efficiency of maize hybrids – Cited by: 12 – Year: 2012

  • 📖 Aflatoxins associated oxidative stress and immunological alterations are mitigated by dietary supplementation of Pichia kudriavzevii in broiler chicks – Cited by: 10 – Year: 2021

  • 📖 Reply Letter-COVID-19 (Novel Coronavirus 2019)-Recent trends – Cited by: 10 – Year: 2020

  • 📖 Potential therapeutic strategies to combat HCC – Cited by: 9 – Year: 2022

  • 📖 Role of Streptococci as etiological agents of dental caries – Cited by: 9 – Year: 2020

  • 📖 Pollen micromorphology among amaranthaceous species from desert rangeland – Cited by: 8 – Year: 2023

  • 📖 Impact of silver dopant on structural, optical and electrical properties of ZnO nanoparticles – Cited by: 8 – Year: 2019

  • 📖 The adverse effects of carbofuran are efficiently counteracted by the supplementation of star anise (Illicium verum) in broiler chicks – Cited by: 7 – Year: 2020

  • 📖 Mitigative Potential of Novel Lactobacillus plantarum TISTR 2076 against the Aflatoxins-Associated Oxidative Stress and Histopathological Alterations in Liver and Kidney of Broiler Chicks – Cited by: 6 – Year: 2022

Conclusion

Dr. Ashiq Ali’s strong academic background, extensive research experience, and high-impact contributions in pathology and immunology make him a strong candidate for the Best Researcher Award. His expertise in molecular diagnostics, vaccine development, and immunology, coupled with his teaching and mentoring skills, align well with the award’s criteria.